Insurer Must Defend Doctor Accused of ‘Fertility Fraud’

Why It Matters

The ruling clarifies insurers’ burden to prove that every allegation fits an exclusion, potentially expanding coverage for doctors sued over fertility fraud. It also signals heightened legal risk for reproductive specialists as state statutes proliferate.

Key Takeaways

• Connecticut court orders insurer to defend fertility doctor
• Ruling hinges on negligence claim lacking intentional conduct
• Excludes insurer from invoking policy exclusions without clear allegation match
• Highlights growing legal exposure for doctors in fertility fraud cases
• No federal law; states enact their own fertility fraud statutes

Pulse Analysis

The Connecticut Appellate Court’s decision in Integris Insurance Co. v. Tohan underscores a pivotal shift in how medical‑malpractice policies are interpreted when fertility‑fraud allegations arise. By emphasizing that insurers must demonstrate a clear, unambiguous link between each claim and a policy exclusion, the court rejected Integris’s argument that the alleged sperm substitution was a sexual act automatically barred from coverage. This nuanced reading separates the medical procedure of IVF from broader sexual conduct exclusions, compelling insurers to draft more precise language if they wish to limit liability for such cases.

For insurers, the ruling serves as a cautionary tale about the importance of policy clarity. Many professional‑liability contracts contain blanket exclusions for intentional wrongdoing, yet the court highlighted that those exclusions only apply when every alleged wrongdoing fits that definition. As fertility clinics expand and genetic testing becomes routine, insurers may need to revisit their underwriting criteria, incorporate explicit carve‑outs for reproductive technologies, and consider higher premiums to offset the growing risk of litigation. This could also drive a market for specialized coverage products tailored to fertility practices, where the line between negligence and intentional fraud is increasingly scrutinized.

The broader industry context reflects a patchwork of state‑level fertility‑fraud statutes, with Texas, California and Florida among the leaders, while no federal framework exists. The lack of uniform regulation leaves patients vulnerable and doctors exposed to civil and criminal liability. Advocacy groups report more than 50 physicians nationwide accused of similar misconduct, suggesting that the Tohan case may be a bellwether for future court decisions. Stakeholders—from clinics to insurers and legislators—must monitor evolving legal standards to mitigate risk, protect patient trust, and shape forthcoming federal policy discussions.